Toleranzia AB (TOL) - Total Liabilities

Latest as of June 2025: Skr9.54 Million SEK ≈ $1.03 Million USD

Based on the latest financial reports, Toleranzia AB (TOL) has total liabilities worth Skr9.54 Million SEK (≈ $1.03 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore TOL shareholders equity momentum to track the company's year-over-year net asset growth rate.

Toleranzia AB - Total Liabilities Trend (2012–2024)

This chart illustrates how Toleranzia AB's total liabilities have evolved over time, based on quarterly financial data. See TOL free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Toleranzia AB Competitors by Total Liabilities

The table below lists competitors of Toleranzia AB ranked by their total liabilities.

Company Country Total Liabilities
Capital Engineering Network Public Company Limited
BK:CEN
Thailand ฿447.12 Million
Logisys Inc
KQ:067730
Korea ₩9.08 Billion
Atta Global Group Bhd
KLSE:7099
Malaysia RM45.13 Million
Wooree E&L Co. Ltd
KQ:153490
Korea ₩30.59 Billion
Vision Sigma
TA:VISN
Israel ILA284.59 Million
Astral Asia Bhd
KLSE:7054
Malaysia RM106.03 Million
Javelin Minerals Ltd
AU:JAV
Australia AU$1.37 Million
Picard Medical, Inc.
NYSE MKT:PMI
USA $18.76 Million

Liability Composition Analysis (2012–2024)

This chart breaks down Toleranzia AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TOL company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.71 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.05 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.05 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Toleranzia AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Toleranzia AB (2012–2024)

The table below shows the annual total liabilities of Toleranzia AB from 2012 to 2024.

Year Total Liabilities Change
2024-12-31 Skr6.40 Million
≈ $688.74K
-7.37%
2023-12-31 Skr6.91 Million
≈ $743.52K
+12.84%
2022-12-31 Skr6.12 Million
≈ $658.93K
+43.59%
2021-12-31 Skr4.26 Million
≈ $458.91K
-8.33%
2020-12-31 Skr4.65 Million
≈ $500.64K
+26.95%
2019-12-31 Skr3.66 Million
≈ $394.37K
+30.76%
2018-12-31 Skr2.80 Million
≈ $301.59K
+33.09%
2017-12-31 Skr2.11 Million
≈ $226.61K
-5.39%
2016-12-31 Skr2.23 Million
≈ $239.52K
-20.67%
2015-12-31 Skr2.81 Million
≈ $301.95K
+97.90%
2014-12-31 Skr1.42 Million
≈ $152.58K
+48.89%
2013-12-31 Skr952.25K
≈ $102.48K
-47.33%
2012-12-31 Skr1.81 Million
≈ $194.57K
--

About Toleranzia AB

ST:TOL Sweden Drug Manufacturers - Specialty & Generic
Market Cap
$13.91 Million
Skr129.25 Million SEK
Market Cap Rank
#26170 Global
#550 in Sweden
Share Price
Skr0.48
Change (1 day)
+0.00%
52-Week Range
Skr0.47 - Skr0.49
All Time High
Skr1.88
About

Toleranzia AB (publ), a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate in clinical trial for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate for the treatment of ANCA vasculitis, an autoimmune blood vessel disease. In … Read more